Sugi Predict

Sugi Predict / Compounds / SCHEMBL6270715

SCHEMBL6270715

SCHEMBL6270715

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)c(C)c32)c(C)c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 3/20 0.54
▸ KDR P35968 10/20 0.51
▸ FLT3 P36888 8/20 0.51
▸ FLT4 P35916 5/20 0.51
▸ KIT P10721 2/20 0.51
▸ PDGFRB P09619 8/20 0.46
▸ FGFR1 P11362 6/20 0.46
▸ RET P07949 3/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ AURKB Q96GD4 4/20 0.45
▸ AURKA O14965 4/20 0.45
▸ MET P08581 3/20 0.45
▸ AURKC Q9UQB9 2/20 0.45
▸ EGFR P00533 2/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ PRKAA1 Q13131 3/20 0.42
▸ FLT1 P17948 2/20 0.42
▸ MAP4K2 Q12851 2/20 0.42
▸ STK3 Q13188 2/20 0.42
▸ CSF1R P07333 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523987 0.88 ALK (0.55) ALKKDRFLT3FLT4KIT
SCHEMBL148379 0.84 KDR (0.66) ALKKDRFLT3FLT4KIT
SCHEMBL143571 0.84 ALK (0.63) ALKKDRFLT3FLT4KIT
SCHEMBL6515226 0.78 ALK (0.59) ALKKDRFLT3FLT4KIT
SCHEMBL6273919 0.77 ALK (0.58) ALKKDRFLT3FLT4KIT
SCHEMBL6273178 0.76 ALK (0.71) ALKKDRFLT3FLT4KIT
SCHEMBL146251 0.76 ALK (0.60) ALKKDRFLT3FLT4KIT
SCHEMBL6519864 0.76 ALK (0.60) ALKKDRFLT3FLT4KIT
SCHEMBL6277459 0.76 ALK (0.60) ALKKDRFLT3FLT4KIT
SCHEMBL2112477 0.76 ALK (0.59) ALKKDRFLT3FLT4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 — — WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 ALK 3814/4885KDR 1077/4885FLT3 3195/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 ALK 327/4885KDR 398/4885FLT3 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.